Asymchem Laboratories
凯莱英
Executive Summary
Asymchem is China's leading small molecule CDMO with ~$1.5B revenue, serving major US pharma including Pfizer (Paxlovid API supplier), BMS, and Lilly. Founded in 1995 by Hao Hong, the company has deep API manufacturing capabilities but faces severe BIOSECURE Act exposure as a likely Category B designation candidate. While operationally strong with proven US pharma relationships, new partnerships carry significant regulatory and political risk.
Structure: Asymchem operates through a relatively straightforward structure with Asymchem Laboratories (002821.SZ) as the listed parent and Asymchem Life Science (Tianjin) as the primary operating subsidiary handling CDMO services. The company appears to use a traditional holding company structure rather than VIE arrangements, which simplifies due diligence but doesn't mitigate BIOSECURE exposure.
Latest Financials
Revenue: 4140288577.71, Net Profit: 710325102.11. Source: East Money (002821)
Period: 2024-09-30 | Source: eastmoney
Key People
| Name | Title | Education | Flags |
|---|---|---|---|
Hao Hong 洪浩 | Founder & Chairman | PhD, North Carolina State University |
Ownership & Shareholder Structure
Asymchem Laboratories → Pfizer
Asymchem manufactured Paxlovid API for Pfizer. Key CDMO relationship.
WuXi AppTec → Asymchem Laboratories
Compete for Big Pharma CDMO contracts. Both under congressional pressure.
Subsidiaries & Affiliates(1)
| Entity | Type | Jurisdiction | Scope | Flags | BIOSECURE |
|---|---|---|---|---|---|
Asymchem Life Science (Tianjin) 凯莱英生命科学技术(天津)有限公司 | operating | mainland china | Small molecule API manufacturing, CDMO services. Major Pfizer Paxlovid API supplier. | CDMO | DIRECT |
Corporate Events
凯莱英：董事会会议日期
CNINFO announcement for Asymchem Laboratories (002821.SZ)
凯莱英：凯莱英医药集团（天津）股份有限公司ESG管理政策
CNINFO announcement for Asymchem Laboratories (002821.SZ)
凯莱英：章程修正案
CNINFO announcement for Asymchem Laboratories (002821.SZ)
凯莱英：董事会薪酬与考核委员会关于公司2025年A股限制性股票激励计划相关事项的核查意见
CNINFO announcement for Asymchem Laboratories (002821.SZ)
凯莱英：关于使用闲置自有资金购买理财产品的公告
CNINFO announcement for Asymchem Laboratories (002821.SZ)
BIOSECURE Act signed — Asymchem at risk
Asymchem is a major small molecule CDMO serving US pharma. Not named in the Act but widely expected to face scrutiny under Category B (OMB designation) due to scale of US pharma dependency.
BIOSECURE Impact: Direct risk as Category B CDMO. Serves multiple Big Pharma clients for API manufacturing.
Asymchem Laboratories Financial Report
Revenue: 4140288577.71, Net Profit: 710325102.11. Source: East Money (002821)
BIOSECURE Risk
Although not explicitly named in the BIOSECURE Act, Asymchem is widely considered a prime Category B designation candidate due to its scale, critical role in US pharma supply chains (especially as Pfizer's Paxlovid API supplier), and congressional pressure targeting Chinese CDMOs
Key Exposures:
- •Major US pharma dependency creates 'biotechnology equipment or services' exposure
- •Paxlovid API manufacturing makes it strategically sensitive
- •Scale and market position make it likely OMB Category B target
- •Congressional pressure specifically targeting Chinese CDMO sector
Mitigation: Limited public disclosure on BIOSECURE mitigation strategies; likely exploring non-China manufacturing options but timeline and feasibility unclear
BD Intelligence
Therapeutic Areas:
Recent Deals: Primarily focused on manufacturing partnerships rather than licensing deals; major Pfizer Paxlovid contract demonstrates capability but increases BIOSECURE risk
Approach: Extreme caution advised - any new partnerships could face immediate BIOSECURE scrutiny and potential forced divestiture; consider alternative CDMOs in non-China jurisdictions
Red Flags
- ⚠High probability Category B designation under BIOSECURE Act
- ⚠Existing US pharma contracts may face forced termination
- ⚠Congressional pressure specifically targeting company's business model
- ⚠Limited disclosed mitigation strategies for regulatory compliance
- ⚠New US partnerships could trigger immediate government scrutiny
Quick Facts
- Key People
- 1
- Subsidiaries
- 1
- CDMO/CRO Subs
- 1
- Genomics Subs
- 0
- Direct BIOSECURE
- 1
- Corp Events
- 7
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 5
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: HKEX annual reports, HKEX Disclosure of Interests
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.